Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Hightide Therapeutics Inc ( (HK:2511) ) just unveiled an announcement.
HighTide Therapeutics, Inc. has scheduled a board meeting for March 27, 2026, to review and approve the audited annual results for the financial year ended December 31, 2025, and to authorize their publication. The meeting will also address other corporate matters, signaling routine governance and financial reporting activities that provide shareholders and the market with updated insight into the company’s performance.
The announcement confirms the current composition of HighTide Therapeutics’ board, listing its executive, non-executive, and independent non-executive directors. This disclosure underscores the company’s compliance with Hong Kong listing requirements on financial transparency and board structure, which are important for investor confidence and regulatory oversight.
The most recent analyst rating on (HK:2511) stock is a Hold with a HK$2.50 price target. To see the full list of analyst forecasts on Hightide Therapeutics Inc stock, see the HK:2511 Stock Forecast page.
More about Hightide Therapeutics Inc
HighTide Therapeutics, Inc. is a biopharmaceutical company focused on developing therapeutic treatments, operating through a corporate structure incorporated in the Cayman Islands and listed on the Hong Kong Stock Exchange under stock code 2511. The company is governed by a board comprising executive, non-executive, and independent non-executive directors, reflecting a standard governance framework for a listed healthcare issuer.
Average Trading Volume: 795,857
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.6B
See more insights into 2511 stock on TipRanks’ Stock Analysis page.